摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-溴-N-丙基咪唑并[1,2-B]哒嗪-6-胺 | 1034621-79-8

中文名称
3-溴-N-丙基咪唑并[1,2-B]哒嗪-6-胺
中文别名
——
英文名称
3-bromo-N-propylimidazo[1,2-b]pyridazin-6-amine
英文别名
——
3-溴-N-丙基咪唑并[1,2-B]哒嗪-6-胺化学式
CAS
1034621-79-8
化学式
C9H11BrN4
mdl
——
分子量
255.117
InChiKey
XRJVIXDRSFFXEX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.62±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    42.2
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险性防范说明:
    P261,P280,P301+P312,P302+P352,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 3: Exploration of effective compounds in arthritis models
    摘要:
    We have discovered imidazo[1,2-b]pyridazine derivatives that show suppressive activity of inflammation in arthritis models. We optimized the substructures of imidazo[1,2-b] pyridazine derivatives to combine potent IKK beta inhibitory activity, TNF alpha inhibitory activity in vivo and excellent pharmacokinetics. The compound we have acquired, which had both potent activities and good pharmacokinetic profiles based on improved physicochemical properties, demonstrated efficacy on collagen-induced arthritis models in mice and rats. (C) 2011 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2011.05.115
  • 作为产物:
    参考文献:
    名称:
    新的二取代咪唑并[1,2-b]哒嗪衍生物作为选择性Haspin抑制剂的设计。合成,结合方式和抗癌生物学评估
    摘要:
    摘要 Haspin是通过调节Aurora B激酶的定位和活性以及组蛋白磷酸化来适当分裂细胞所需的一种有丝分裂蛋白激酶。在此建立了一系列基于CHR-6494和结构活性关系的咪唑并哒嗪。提出了对人的Haspin和其他几种蛋白激酶的前导结构的抑制活性的评估。结合晶体结构和有效的对接模型,对铅结构进行了快速优化,最佳的抑制剂在体外对Haspin表现出有效的抑制活性,IC 50在6至100 nM之间。所开发的抑制剂在2D和球形培养物中显示出对各种人类癌细胞系的抗增殖特性,并显着抑制了骨肉瘤U-2 OS细胞的迁移能力。值得注意的是,我们证明了我们的先导化合物在人细胞中是强大的Haspin抑制剂,并且由于对CDK1 / CyclinB的选择性提高而没有阻止G2 / M细胞周期的转变。
    DOI:
    10.1080/14756366.2020.1825408
点击查看最新优质反应信息

文献信息

  • 6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS
    申请人:CHEN Hwang-Hsing
    公开号:US20080153813A1
    公开(公告)日:2008-06-26
    Methods for using 6-aminoimidazo[1,2-b]pyridazine analogs are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of 6-aminoimidazo[1,2-b]pyridazine analogs, are disclosed herein.
    本文披露了使用6-氨基咪唑并[1,2-b]吡啶嗪类似物治疗rho激酶介导的疾病或rho激酶介导的症状的方法,包括控制眼压和治疗青光眼。本文还披露了用于治疗眼部疾病如青光眼,并且对控制眼压有益的眼科药物组合物,该组合物包括有效量的6-氨基咪唑并[1,2-b]吡啶嗪类似物。
  • 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
    申请人:Alcon Research, Ltd.
    公开号:US07820670B2
    公开(公告)日:2010-10-26
    Methods for using 6-aminoimidazo[1,2-b]pyridazine analogs are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of 6-aminoimidazo[1,2-b]pyridazine analogs, are disclosed herein.
    本文披露了使用6-氨基咪唑[1,2-b]吡嗪类似物治疗rho激酶介导的疾病或rho激酶介导的病症的方法,包括控制眼内压和治疗青光眼。本文还披露了眼科制药组合物,对于治疗眼部疾病如青光眼,以及控制眼内压具有额外的用途,该组合物包括6-氨基咪唑[1,2-b]吡嗪类似物的有效量。
  • US7820670B2
    申请人:——
    公开号:US7820670B2
    公开(公告)日:2010-10-26
  • Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 3: Exploration of effective compounds in arthritis models
    作者:Hiroki Shimizu、Tomonori Yamasaki、Yoshiyuki Yoneda、Fumihito Muro、Tomoaki Hamada、Takanori Yasukochi、Shinji Tanaka、Tadashi Toki、Mika Yokoyama、Kaoru Morishita、Shin Iimura
    DOI:10.1016/j.bmcl.2011.05.115
    日期:2011.8
    We have discovered imidazo[1,2-b]pyridazine derivatives that show suppressive activity of inflammation in arthritis models. We optimized the substructures of imidazo[1,2-b] pyridazine derivatives to combine potent IKK beta inhibitory activity, TNF alpha inhibitory activity in vivo and excellent pharmacokinetics. The compound we have acquired, which had both potent activities and good pharmacokinetic profiles based on improved physicochemical properties, demonstrated efficacy on collagen-induced arthritis models in mice and rats. (C) 2011 Elsevier Ltd. All rights reserved.
  • Design of new disubstituted imidazo[1,2-<i>b</i>]pyridazine derivatives as selective Haspin inhibitors. Synthesis, binding mode and anticancer biological evaluation
    作者:Jonathan Elie、Omid Feizbakhsh、Nathalie Desban、Béatrice Josselin、Blandine Baratte、Amandine Bescond、Julien Duez、Xavier Fant、Stéphane Bach、Dominique Marie、Matthieu Place、Sami Ben Salah、Agnes Chartier、Sabine Berteina-Raboin、Apirat Chaikuad、Stefan Knapp、Fabrice Carles、Pascal Bonnet、Frédéric Buron、Sylvain Routier、Sandrine Ruchaud
    DOI:10.1080/14756366.2020.1825408
    日期:2020.1.1
    Abstract Haspin is a mitotic protein kinase required for proper cell division by modulating Aurora B kinase localisation and activity as well as histone phosphorylation. Here a series of imidazopyridazines based on the CHR-6494 and Structure Activity Relationship was established. An assessment of the inhibitory activity of the lead structures on human Haspin and several other protein kinases is presented
    摘要 Haspin是通过调节Aurora B激酶的定位和活性以及组蛋白磷酸化来适当分裂细胞所需的一种有丝分裂蛋白激酶。在此建立了一系列基于CHR-6494和结构活性关系的咪唑并哒嗪。提出了对人的Haspin和其他几种蛋白激酶的前导结构的抑制活性的评估。结合晶体结构和有效的对接模型,对铅结构进行了快速优化,最佳的抑制剂在体外对Haspin表现出有效的抑制活性,IC 50在6至100 nM之间。所开发的抑制剂在2D和球形培养物中显示出对各种人类癌细胞系的抗增殖特性,并显着抑制了骨肉瘤U-2 OS细胞的迁移能力。值得注意的是,我们证明了我们的先导化合物在人细胞中是强大的Haspin抑制剂,并且由于对CDK1 / CyclinB的选择性提高而没有阻止G2 / M细胞周期的转变。
查看更多